Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Elizabeth Smyth MD Advisory Board

Roger Stupp MD Advisory Board

Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · September 19, 2017

Updates on Adjuvant Therapy for mRCC From ESMO 2017

Interview by

Jennifer N. Caudle DO

Interview with

Eric Jonasch MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Eric Jonasch MD

featured

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

JAMA Oncol · December 05, 2024
story of the week

Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma

Lancet Oncol · December 05, 2024
featured

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

Conference Coverage · December 04, 2024
featured

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

Conference Coverage · December 04, 2024
featured

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Clin. Cancer Res · December 04, 2024
featured

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

ESMO Open · December 04, 2024
featured

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Ann. Oncol · December 04, 2024
featured

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Lancet Oncol · December 02, 2024

updated
story of the week

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Lancet · December 02, 2024
featured

Glutaminase Inhibition Plus Azacitidine for Myelodysplastic Syndromes

Nat Cancer · November 27, 2024

updated
featured

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Lancet · November 27, 2024

Renal Cell Carcinoma

Updates on Adjuvant Therapy for mRCC From ESMO 2017

Additional Info

Further Reading

Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma

Neoadjuvant and Adjuvant Toripalimab for Locoregionally Advanced Nasopharyngeal Carcinoma

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Glutaminase Inhibition Plus Azacitidine for Myelodysplastic Syndromes

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Related Videos